SFX by Ex Libris Inc.

Title:	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Source:	Nature [0028-0836] Johannessen, C M yr:2010

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Nazarian, R. "Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation." Nature 468.7326 (2010): 973-977.
description	2.	Joseph, Eric W. "The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner." Proceedings of the National Academy of Sciences of the United States of America 107.33 (2010): 14903-14908.
description	3.	Poulikakos, Poulikos I. "RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)." Nature 480.7377 (2011): 387-390.
description	4.	Solit, David B B. "BRAF mutation predicts sensitivity to MEK inhibition." Nature 439.7074: 358-362.
description	5.	Lange-Carter, G L A. "A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf." Science 260.5106 (1993): 315-9.
description	6.	Bollag, Hirth P. "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma." Nature 467.7315 (2010): 596-599.
description	7.	Kolch, W. "Coordinating ERK/MAPK signalling through scaffolds and inhibitors." Nature reviews. Molecular cell biology 6.11 (2005): 827-37.
description	8.	SCHNEIDER, W. "Cytochemical studies of mammalian tissues; the isolation of cell components by differential centrifugation: a review." Cancer research 11.1 (1951): 1-22.
description	9.	Druker, B J J. "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia." The New England journal of medicine 344.14 (2001): 1031-7.
description	10.	Poulikakos, Poulikos I. "RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF." Nature 464.7287 (2010): 427-430.
description	11.	Garraway, L. "Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma." Nature 436.7047 (2005): 117-22.
description	12.	Zhou, Y. "Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas." Nature Biotechnology 28.1 (2010): 71-78.
description	13.	Pratilas, C. "V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway." Proceedings of the National Academy of Sciences of the United States of America 106.11 (2009): 4519-4524.
description	14.	Chen, W. "Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins." Endocrinology 141.3 (2000): 1263-72.
description	15.	Khazak, V. "Selective Raf inhibition in cancer therapy." Expert Opinion on Therapeutic Targets 11.12 (2007): 1587-1609.
description	16.	Downward, J. "Cancer biology: signatures guide drug choice." Nature 439.7074: 274-275.
description	17.	Bollag, G. "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity." Proceedings of the National Academy of Sciences of the United States of America 105.8 (2008): 3041-6.
description	18.	Horwitz, Susan Band B. "Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants." Cancer research 65.7 (2005): 2854-60.
description	19.	Adzhubei, Ivan A. "A method and server for predicting damaging missense mutations." Nature Methods 7.4 (2010): 248-249.
description	20.	Cichowski, K. "Drug discovery: inhibitors that activate." Nature 464.7287 (2010): 358-359.